Tags

Type your tag names separated by a space and hit enter

Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum.
Complement Ther Med. 2009 Jun; 17(3):176-8.CT

Abstract

OBJECTIVES

To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous mono-extract of Piper methysticum (kava). The significance of the qualitative element of our clinical trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebo-controlled, double-blind, cross-over trial involving 60 adult participants (18-65) with elevated stable anxiety and varying levels of depressive symptoms.

AIMS

The aims of KADSS are: (1) to determine whether an aqueous standardised extract of kava is effective for the treatment of anxiety; (2) to assess the effects of kava on differing levels of depression; and (3) to explore participants' experience of taking kava via qualitative research. The study also provides preliminary assessment of the safety of an aqueous extract of kava in humans.

CONCLUSION

If results reveal that the aqueous kava preparation exerts significant anxiolytic effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. This may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of anxiety disorders.

Authors+Show Affiliations

School of Medicine, University of Queensland, Australia. j.sarris@uq.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19398072

Citation

Sarris, J, et al. "Kava Anxiety Depression Spectrum Study (KADSS): a Mixed Methods RCT Using an Aqueous Extract of Piper Methysticum." Complementary Therapies in Medicine, vol. 17, no. 3, 2009, pp. 176-8.
Sarris J, Kavanagh DJ, Adams J, et al. Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum. Complement Ther Med. 2009;17(3):176-8.
Sarris, J., Kavanagh, D. J., Adams, J., Bone, K., & Byrne, G. (2009). Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum. Complementary Therapies in Medicine, 17(3), 176-8. https://doi.org/10.1016/j.ctim.2009.01.001
Sarris J, et al. Kava Anxiety Depression Spectrum Study (KADSS): a Mixed Methods RCT Using an Aqueous Extract of Piper Methysticum. Complement Ther Med. 2009;17(3):176-8. PubMed PMID: 19398072.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum. AU - Sarris,J, AU - Kavanagh,D J, AU - Adams,J, AU - Bone,K, AU - Byrne,G, Y1 - 2009/02/07/ PY - 2008/09/09/received PY - 2009/01/06/revised PY - 2009/01/06/accepted PY - 2009/4/29/entrez PY - 2009/4/29/pubmed PY - 2009/7/8/medline SP - 176 EP - 8 JF - Complementary therapies in medicine JO - Complement Ther Med VL - 17 IS - 3 N2 - OBJECTIVES: To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous mono-extract of Piper methysticum (kava). The significance of the qualitative element of our clinical trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebo-controlled, double-blind, cross-over trial involving 60 adult participants (18-65) with elevated stable anxiety and varying levels of depressive symptoms. AIMS: The aims of KADSS are: (1) to determine whether an aqueous standardised extract of kava is effective for the treatment of anxiety; (2) to assess the effects of kava on differing levels of depression; and (3) to explore participants' experience of taking kava via qualitative research. The study also provides preliminary assessment of the safety of an aqueous extract of kava in humans. CONCLUSION: If results reveal that the aqueous kava preparation exerts significant anxiolytic effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. This may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of anxiety disorders. SN - 1873-6963 UR - https://www.unboundmedicine.com/medline/citation/19398072/Kava_Anxiety_Depression_Spectrum_Study__KADSS_:_a_mixed_methods_RCT_using_an_aqueous_extract_of_Piper_methysticum_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0965-2299(09)00002-8 DB - PRIME DP - Unbound Medicine ER -